Publications by authors named "Erica D Dommasch"
Importance: Masculinizing gender-affirming hormonal therapy is associated with the development of acne. While isotretinoin is a highly effective acne treatment, little is known about its effectiveness and safety among transgender and gender-diverse individuals receiving gender-affirming hormonal therapy.
Objective: To evaluate clinical outcomes of isotretinoin among transgender and gender-diverse individuals receiving gender-affirming hormonal therapy.
Background: Androgenetic alopecia (AGA) is a significant challenge for many transgender and gender diverse (TGD) patients, but the rate of AGA among TGD patients receiving gender-affirming hormone therapy (GAHT) compared to cisgender patients has not yet been studied on a large scale.
Objective: We examined the incidence of AGA among TGD patients receiving GAHT compared to cisgender patients.
Methods: Retrospective cohort study using electronic health records from 37,826 patients seen at Fenway Health between August 1, 2014, and August 1, 2020.
Androgenetic alopecia (AGA) management is a significant clinical and therapeutic challenge for transgender and gender-diverse (TGD) patients. Although gender-affirming hormone therapies affect hair growth, there is little research about AGA in TGD populations. After reviewing the literature on approved treatments, off-label medication usages, and procedures for treating AGA, we present treatment options for AGA in TGD patients.
View Article and Find Full Text PDFThis cohort study examines the proportion of transgender and gender-diverse individuals patients receiving masculinizing hormone therapy who developed androgenetic alopecia.
View Article and Find Full Text PDFImportance: Acne is a common condition among transgender patients receiving masculinizing hormone therapy (MHT), but the incident risk and predictors of developing acne in this population have not yet been studied on a large scale.
Objective: To assess risk of acne among a large population of transgender patients receiving MHT and clinical risk factors for acne diagnosis.
Design, Setting, And Participants: A retrospective cohort study that included 988 patients who started MHT between January 1, 2014, and December 31, 2017, with at least 1 year of follow-up was performed.
Objective: To update guidance regarding the management of psoriatic disease during the COVID-19 pandemic.
Study Design: The task force (TF) includes 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation staff.
Objective: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.
Study Design: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff.
Importance: There is a need for better understanding of the comparative safety of systemic medications used in the treatment of psoriasis.
Objective: To compare the risk of serious infection associated with biologic and nonbiologic systemic medications in patients with psoriasis.
Design, Setting, And Participants: An observational cohort study was conducted using medical and outpatient pharmacy claims from 2 large US health insurance claims databases from January 1, 2003, through September 30, 2015.
Background: Nonadherence to systemic treatments for psoriasis leads to treatment failure and increased health care utilization.
Objective: Examine drug utilization patterns and adherence of new users of systemic medications for psoriasis.
Methods: We conducted a retrospective, comparative cohort study using a large US health insurance claims database including psoriasis patients who were new users of acitretin, adalimumab, etanercept, methotrexate, or ustekinumab.
Importance: The effect of vaccination on emergency department (ED) utilization for herpes zoster (HZ) has not been examined to date.
Objective: To determine trends in US ED utilization and costs associated with HZ.
Design, Setting, And Participants: The Nationwide Emergency Department Sample data set was examined for temporal trends in the number of visits and costs for treatment of HZ in EDs in the United States from January 1, 2006, through December 31, 2013.
Background: There is a need to better understand the safety of tumor necrosis factor (TNF) inhibitors in patients with psoriatic disease in whom TNF inhibitors are frequently used as monotherapy.
Objective: We sought to examine the risks of infection and malignancy with the use of TNF antagonists in adult patients with psoriatic disease.
Methods: We conducted a systematic search for trials of TNF antagonists for adults with plaque psoriasis and psoriatic arthritis.
Psoriasis is a chronic Th-1 and Th-17 inflammatory disease. Chronic inflammation has also been associated with atherosclerosis and thrombosis. The purpose of this study was to determine the risk of stroke in patients with psoriasis.
View Article and Find Full Text PDF